AnkeBio Showcases Multiple Pipeline Products
Including Regulatory T-Cell Injection at the 4th Sci-Tech Fair
April 26–28, 2026 - The 4th China (Anhui) Science and Technology Innovation Achievement Transformation Fair (abbreviated as the Sci-Tech Fair), hosted by the People’s Government of Anhui Province with Shanghai as the Guest Province of Honor, was successfully held at the Hefei Binhu International Convention and Exhibition Center. As a National Innovative (Pilot) Enterprise and National Technological Innovation Demonstration Enterprise, Anhui Anke Biotechnology (Group) Co., Ltd. (AnkeBio) presented a number of pipeline products in the Life Sciences section of the Fair. Among them, the Regulatory T-cell (Treg) injection and other cutting-edge products fully demonstrated the core innovative strength of Anhui’s biomedical industry.
Regulatory T-cell (Treg) injection is an innovative immunomodulatory product designed to regulate immune responses. It plays a critical role by modulating the immune reaction in patients with graft-versus-host disease (GVHD) following umbilical cord blood transplantation. Regulatory T cells (Tregs) are a specialized subset of T cells that suppress autoimmunity through multiple mechanisms, including secretion of inhibitory cytokines, cell-mediated killing, contact-dependent suppression, metabolic competition, and modulation of antigen presentation. The product is currently being evaluated in investigator-initiated trials (IITs) across multiple clinical indications at the First Affiliated Hospital of the University of Science and Technology of China and the Second Affiliated Hospital of Anhui Medical University
